Publicacions en col·laboració amb investigadors/ores de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (11)

2024

  1. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

  2. TRIM33 loss in multiple myeloma is associated with genomic instability and sensitivity to PARP inhibitors

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities

    Cancers, Vol. 15, Núm. 2

2022

  1. RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation

    Experimental Hematology and Oncology, Vol. 11, Núm. 1

2020

  1. FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma

    Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 7, pp. 4171-4182

2019

  1. Factors regulating microRNA expression and function in multiple myeloma

    Non-coding RNA, Vol. 5, Núm. 1

2017

  1. DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  2. Targeting ongoing DNA damage in multiple myeloma: Effects of DNA damage response inhibitors on plasma cell survival

    Frontiers in Oncology, Vol. 7, Núm. MAY

2016

  1. Molecular mechanisms of p53 deregulation in cancer: An overview in multiple myeloma

    International Journal of Molecular Sciences, Vol. 17, Núm. 12

2008

  1. Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734

    Cancer Research, Vol. 68, Núm. 23, pp. 9779-9787

2006

  1. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin

    Cancer Research, Vol. 66, Núm. 16, pp. 8155-8162